Director Regulatory Affairs
Kerstin joined the company as Director RA/QA with the acquisition of Sividon Diagnostics GmbH in June 2016 and assumed responsibility for Regulatory Affairs for the diagnostic kit business. In addition, she manages the Sividon site in Cologne. As a cofounder and head of RA/QA of Sividon, she implemented and maintained an ISO 13485 certified QM system. In addition, she had the regulatory responsibility for CE marking the EndoPredict test and the EndoPredict Report Generator as well as preparing a 510(k) submission to FDA for these products. She obtained a PhD in molecular biology and spent several years of academic research in renowned research institutes (EMBL, Heidelberg and Max-Planck-Institute for Developmental Biology, Tuebingen). Since 2000, she held different management positions in research, development and project management in the diagnostic industry at Bayer Healthcare, Siemens and Sividon in Germany and the United States.
Country Manager Italy
Chief Commercial Officer, Europe
Raymond Francot joined Myriad Genetics in January 2018 and has 25 years of experience in the international life sciences industry. Before joining Myriad Genetics, Mr. Francot was Vice president, Regional General Manager for Vertex Pharmaceuticals GmbH. In this role, he was responsible for Vertex’s Commercial Operations in Germany and Central and Eastern Europe. During his time at Vertex, Mr. Francot has established country operations in the various countries in his geographic area and ensured market access for the Vertex CF portfolio.
Prior to joining Vertex, Mr. Francot was General Manager at Gilead Sciences Germany GmbH where he developed the company’s HIV franchise in Germany, Austria and Switzerland. Mr. Francot’s first roles in the life sciences industry were with Baxter Healthcare where he held various international commercial positions in the renal division.
Raymond Francot has a MBA from the Erasmus University of Rotterdam (Netherlands) and completed his law studies at the University of Maastricht(Netherlands).
Gary A. King
Executive Vice President, International Operations
Country Manager France
He is now focusing on France as business and team are growing significantly since the first Myriad product is reimbursed in the country. Mr. Korman has been employed in the life sciences industry for 30 years. He served as CEO in a French biotech company, Fluigent, a spin-off of Curie Institute, and prior to that, he was CEO at Alexion Pharmaceutical France from the startup of the company and a Senior Member of Alexion Europe Leadership Team, spending 3 years establishing the business from MAA to pricing and first years of sales. Prior to Alexion, he built an extensive experience of the Pharma industry as VP in different international consulting firms. Mr. Korman has an MA Political Sciences and MBA from HEC.
Director, International Medical Affairs
Ralf Kronenwett joined Myriad Genetics with the acquisition of Sividon Diagnostics in June 2016 and holds the position of Director International Medical Affairs. He received his medical degree from the University of Heidelberg. After serving as a resident physician at the University Hospital Heidelberg, Ralf Kronenwett was a research group leader at the Clinical Cooperation Unit Molecular Hematology/Oncology of the German Cancer Research Centre in Heidelberg. In 1999, he moved to the University Hospital Dusseldorf, qualified as an Assistant Professor of Molecular Medicine and focused on molecular therapeutics and diagnostics in hematology/oncology as well as biology and therapeutic use of hematopoietic stem cells. From 2006 to 2010, he held positions as senior scientist at Bayer HealthCare and Siemens Healthcare Diagnostics and was working on prognostic and predictive biomarkers in breast cancer. In 2010, Ralf Kronenwett co-founded Sividon Diagnostics GmbH and held the positions of the Chief Medical Officer and Chief Scientific Officer (CMO/CSO). He was responsible for Medical Affairs, for R&D activities and for the development of the breast cancer prognosis test EndoPredict. Ralf Kronenwett was involved in several international research projects and is a coauthor of more than 90 research journal publications.
Director of International Sales
Director Customer and Kits Operations
Frank Nowas has worked in various roles within the In-Vitro-Diagnostics and Life Science industry for 21 years. After many years in technical field service and product support functions with Beckman Coulter in Europe, he became European Project Manager for laboratory automation and led later on the Clinical Diagnostics Service Germany West. He then spent nearly five years with the German subsidiary of Waters Inc. as National Service Manager. There he managed Field Service, Customer Support and Customer training. Excellent customer service for clinical customers, pharmaceutical and chemistry industry, universities and public institutions have been the main focus of his work there. Most recently, Mr. Nowas served as Director Services International in the area of gastroenterology. His responsibilities contained optimization of customer service for direct customers and distributors throughout the world, continuous improvement to the repair center as well as creating technical support capabilities outside Europe.
Mr. Nowas received his diploma in Biomedical Engineering from the University of Applied Science in Aachen.
Country Manager Canada
Country Manager UK and Ireland
David’s scientific career began in drug discovery following a PhD and Post-doctoral research in synthetic organic chemistry. After some years as a medicinal chemist, David moved into a more commercial role before joining Fisher Scientific UK Ltd as a sales representative. Following an MBA at Imperial College, London focused on healthcare, David Joined MeadWestvaco a world leading packaging manufacturer in business development progressing to European Sales Director for the Adherence Packaging and Pump Dispenser business. A second spell at Thermo Fisher Scientific saw David managing the UK, Ireland and Netherlands Clinical Diagnostics business, bringing together the innovative biomarker business with the well-established Drugs of Abuse and quality controls portfolio. David brings a good deal of experience in UK market access, having worked closely with NICE, the NIHR Diagnostic Evidence Cooperatives and NHS England. He has expertise in Health Economics, Decision Impact modelling and guideline processes.